Annals of Translational Medicine · 2020 · 61 citations · 23 references
MedicineOncologyPharmacologyCancer PharmacologyCellular PharmacologyMolecular OncologyCancer Cell SignalingCancer Stem Cell BiologyCancer Stem CellsOncogenic Signaling PathwaysOncology PharmacologyOxidative Stress In CarcinogenesisCancer Cell Proliferation InhibitionCancer Stem Cell - Mediated ResistanceCell Viability AssaysEpithelial-mesenchymal Transition MarkersMesenchymal TransitionNf-κb SignalingRodent Tumor ModelsSphere Formation Assays
BACKGROUND: Taxifolin is a natural flavonoid with anti-oxidant and anti-proliferative properties. In this study, we investigated the stemness-related inhibitory effects of taxifolin in two lung cancer cell lines, A549 and H1975, as well as in A549 xenografts. METHODS: A549 and H1975 cells, as well as A549 xenograft BALB/c mice were treated with taxifolin. Cell viability, stemness, mobility and protein expression were tested with Cell counting kit-8 (CCK-8), Colony formation assay, Flow cytometry, Transwell, Western blot and Immunohistochemistry, respectively. RESULTS: CCK-8 exhibited an obvious toxicity of taxifolin to both cell lines at higher dose. Then taxifolin of 0, 25, 50, and 100 µM/L were subsequently used. Taxifolin exhibited inhibitory effects on stemness and sphere formation, reduced protein expression of SOX2 and OCT4, and reduced CD133-positive cells. Furthermore, taxifolin decreased invasive cells, reduced N-cadherin and vimentin while increased E-cadherin expression, indicating that epithelial-mesenchymal transition (EMT) was inhibited. All of the effects observed were exhibited in a dose-dependent manner, and A549 cells proved to be more sensitive to taxifolin than H1975 cells. Taxifolin inactivated PI3K and TCF4 protein phosphorylation; however, taxifolin was not observed to have an effect on NF-κB P65 or STAT3. Taxifolin also suppressed tumor growth in A549 xenograft BALB/c mice, with decreased SOX2 and OCT4 expression and inhibited PI3K and TCF4. CONCLUSIONS: In summary, taxifolin inhibited stemness and EMT in lung cancer cells possibly via the inactivation of PI3K and OCT4. Taxifolin could be a potential prodrug or serve as an adjuvant in lung cancer treatment.
23
Wei-Jiunn Lee, Lan-Feng Wu, Wen-Kang Chen et al. · Chemico-Biological Interactions · 2006 · 129 citations
Suhail Razak, Tayyaba Afsar, Asad Ullah et al. · BMC Cancer · 2018 · 107 citations · Full text
Medicine, Oncology, Pharmacology +17
Taxifolin Suppresses UV-Induced Skin Carcinogenesis by Targeting EGFR and PI3K
Naomi Oi, Hanyong Chen, Myoung Ok Kim et al. · Cancer Prevention Research · 2012 · 82 citations
Medicine, Oncology, Pharmacology +17